Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTUNASDAQ:AMRNNASDAQ:AVTENASDAQ:SBOT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$10.33+2.3%$8.53$5.51▼$11.73$201.77MN/A48,059 shs46,719 shsAMRNAmarin$11.11+1.1%$9.79$7.08▼$18.00$230.08M0.6676,229 shs30,664 shsAVTEAerovate Therapeutics$7.32-2.3%$59.53$43.75▼$884.98$212.17M0.9518,596 shs226,035 shsSBOTStellar Biotechnologies$11.34-2.5%$59,624.23$0.75▼$3.25$60.44MN/A2.95 million shs6.28 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics+2.28%-2.09%+14.78%+34.33%+1,032,999,900.00%AMRNAmarin+1.09%+5.01%+7.24%-5.70%-36.28%AVTEAerovate Therapeutics-2.27%-1.08%-92.37%-91.18%-98.84%SBOTStellar Biotechnologies+21.15%+23.86%+120.68%-3.16%+298.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAMRNAmarin0.365 of 5 stars1.04.00.00.01.50.00.0AVTEAerovate Therapeutics1.4809 of 5 stars3.00.00.00.03.21.70.6SBOTStellar BiotechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 3.00Buy$20.5098.45% UpsideAMRNAmarin 2.00Hold$7.00-36.99% DownsideAVTEAerovate Therapeutics 2.00Hold$78.75975.82% UpsideSBOTStellar Biotechnologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SBOT, AMRN, AVTE, and ACTU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2025ACTUActuate TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/17/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $7.003/17/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AAMRNAmarin$214.11M1.07N/AN/A$1.35 per share8.23AVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ASBOTStellar Biotechnologies$210K287.82N/AN/A$2.12 per share5.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$24.75MN/A0.00∞N/AN/AN/AN/AN/AAMRNAmarin-$59.11M-$3.64N/AN/AN/A-16.33%-7.22%-4.96%7/30/2025 (Estimated)AVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%8/11/2025 (Estimated)SBOTStellar Biotechnologies-$5.03M-$1.76N/AN/AN/A-1,782.64%-51.12%-48.37%N/ALatest SBOT, AMRN, AVTE, and ACTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ACTUActuate Therapeutics-$0.26-$0.32-$0.06-$0.32N/AN/A5/7/2025Q1 2025AMRNAmarin-$0.06-$0.04+$0.02-$0.04$50.75 millionN/A4/25/2025Q4 2024AVTEAerovate Therapeutics-$10.50-$3.15+$7.35-$0.09N/AN/A3/27/2025Q4 2024AVTEAerovate Therapeutics-$6.65-$6.65N/A-$0.19N/AN/A3/12/2025Q4 2024AMRNAmarin-$1.20-$2.40-$1.20-$0.12$32.37 million$62.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/AAMRNAmarinN/AN/AN/AN/AN/AAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ASBOTStellar BiotechnologiesN/AN/AN/AN/AN/ALatest SBOT, AMRN, AVTE, and ACTU DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/9/2025AVTEAerovate Therapeutics$84.004/29/20254/25/20254/28/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A1.681.68AMRNAmarinN/A3.232.11AVTEAerovate TherapeuticsN/A8.788.78SBOTStellar BiotechnologiesN/A9.248.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/AAMRNAmarin22.25%AVTEAerovate TherapeuticsN/ASBOTStellar Biotechnologies1.69%Insider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics69.34%AMRNAmarin3.30%AVTEAerovate Therapeutics24.90%SBOTStellar Biotechnologies7.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1019.53 millionN/AN/AAMRNAmarin36020.71 million402.62 millionOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableSBOTStellar Biotechnologies255.33 millionN/ANot OptionableSBOT, AMRN, AVTE, and ACTU HeadlinesRecent News About These CompaniesServe Robotics ties up with Alphabet's unit for drone deliveries, launching pilot in TexasOctober 1, 2024 | reuters.comAre robots the future of food delivery? Serve Robotics thinks soMay 5, 2024 | finance.yahoo.comUber, Nvidia-backed Serve Robotics hits public markets with $40M splashApril 18, 2024 | techcrunch.comStellar Blade Demo WalkthroughApril 17, 2024 | ign.comBeen StellarMarch 11, 2024 | nme.comThe real reason Terry Biviano signed up to be a HousewifeOctober 31, 2023 | dailytelegraph.com.auZach Wilson’s stellar day at Jets camp includes long touchdown throwJuly 30, 2023 | nypost.comCaterpillar's Stellar Move To Attract High-Quality EmployeesJune 7, 2023 | forbes.comAudio-Technica AT2020USB-X review - Simple for stellar streamingMay 10, 2023 | techradar.comRavens Expect to Bring Back Stellar Offensive LineFebruary 26, 2023 | si.com2023 NFL combine: Detroit Lions could re-invest in their stellar offensive lineFebruary 26, 2023 | mlive.comStellar Bancorp, Inc. Declares Quarterly DividendFebruary 26, 2023 | benzinga.comMSU-Mankato rallies past Dragons women with stellar 3rd-quarter performanceFebruary 5, 2023 | inforum.comO's closer Felix Bautista goes on DL ending stellar rookie yearOctober 5, 2022 | cbsnews.comDaniel Ryan one of the stellar cast members of new gripping BBC thriller Crossfire partly set in LeicesterSeptember 24, 2022 | leicestermercury.co.ukNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSBOT, AMRN, AVTE, and ACTU Company DescriptionsActuate Therapeutics NASDAQ:ACTU$10.31 +0.21 (+2.12%) As of 05/23/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Amarin NASDAQ:AMRN$11.11 +0.12 (+1.09%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$11.18 +0.07 (+0.63%) As of 05/23/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Aerovate Therapeutics NASDAQ:AVTE$7.32 -0.17 (-2.27%) As of 05/22/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Stellar Biotechnologies NASDAQ:SBOTStellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
